Individuals tend to be more affected by vitiligo if it is visible on their face or hands, said David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center.
David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, explains how vitiligo can impact a patient's quality of life, and why oral and topical treatment options are important.
Transcript
How does vitiligo affect a patient’s quality of life?
Vitiligo can be very impactful on patients' lives. We know from our research that oftentimes teenagers are very affected by their vitiligo. If patients have involvement of exposed areas such as the face or hands, they often are more affected by their disease. Additionally, if the disease is uncontrolled or progressive and somebody doesn't know when are they going to get another lesion, that also can really affect their quality of life. But every patient is different and some people are not as bothered, and we need to be able to accept everybody who has vitiligo and, for those who want to repigment, hopefully provide them that option.
Do you see a difference in adherence between topical and oral treatments?
It's important to have both an oral option to treat diseases as well as topicals. Orals can be particularly helpful for patients who have a large body surface area, or who find it inconvenient to use topicals, or maybe have progressive or unstable disease, whereas topical treatments are great because you avoid or minimize systemic exposure, and often are great for people who have more localized disease.
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More